A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is essential for tumor development, yet mTOR inhibitors have yielded modest results. This phase 1 study investigated the mTORC1/mTORC2 inhibitor CC‐223 in patients with advanced cancer. METHODS: Patients with advanced solid tumors or multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bendell, Johanna C., Kelley, Robin K., Shih, Kent C., Grabowsky, Jennifer A., Bergsland, Emily, Jones, Suzanne, Martin, Thomas, Infante, Jeffrey R., Mischel, Paul S., Matsutani, Tomoo, Xu, Shuichan, Wong, Lilly, Liu, Yong, Wu, Xiaoling, Mortensen, Deborah S., Chopra, Rajesh, Hege, Kristen, Munster, Pamela N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832308/
https://www.ncbi.nlm.nih.gov/pubmed/26177599
http://dx.doi.org/10.1002/cncr.29422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832308/
https://www.ncbi.nlm.nih.gov/pubmed/26177599
http://dx.doi.org/10.1002/cncr.29422

Ejemplares similares